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Background: The study aims to survey longstanding funduscopic and functional outcomes of age-related macular
degeneration (AMD) after ranibizumab treatment and verify the accuracy of a new method to compare the retinal
thickness measured with different optical coherence tomography (OCT) tools.
Methods: Case series included 314 eyes with 2–4 years of follow-up. Main Outcome Measures were visual acuity
(VA), number of injections, retinal thickness, OCT morphology, and final macular funduscopic status.
Results: One hundred twenty-two men and 177 women (mean age, 78.3 years) were included. The mean time to the
first injection was 17.3 ± 14.6 days. Initial VA was O.8(20/125) ± 0.5; 0.7(20/100) ± 0.5 at 3 months; 0.8(20/125) ± 0.5 at
a year; 1(20/200) ± 0.6 at year 2; 1(20/200) ± 0.6 at year 3 and 1.1(20/250) ± 0.6 at year 4. Number of visits at 3 months
was 2.7 ± 0.8; 7.3 ± 2.1 at a year; 5.2 ± 2.7 along the 2nd year; 3.9 ± 2.3 at year 3 and 3.6 ± 2.2 at year 4. Number of
injections at 3 months was 2.6 ± 0.5; 3.9 ± 1.5 at a year; 1.1 ± 1.5 along the 2nd year; 1.5 ± 2.4 at year 3 and 1.8 ± 3.1
at year 4. Patients with worse VA outcomes received more injections and were older. The formula to calculate changes
in retinal thickness showed a 30% reduction in thickness, which correlated well with the OCT morphology. Patients
with polypoidal choroidal vasculopathy (PCV) had a worse final outcome. The final disciform macular status (37%)
was related to fewer injections and a greater decrease in thickness. Final well-preserved maculas (12.%) needed more
injections and treatment changes; those that were atrophic at the final visit (30.8%) had a worse initial VA and greater
decrease in thickness at the 3-month visit.
Conclusions: Younger patients had better final outcomes. Our method to compare retinal thickness using different
OCT tools worked well. The final visual outcome after a long follow-up was poor, which may be related to advanced
age, poor initial VA, and the high incidence of final fibrosis or atrophy.
Keywords: Age-related macular degeneration (AMD), Ranibizumab, Optical coherence tomography (OCT), Atrophy,
Disciform scar, OutcomeBackground
Age-related macular degeneration (AMD) is the main
cause of legal blindness among individuals older than
65 years in developed countries [1]. The management of
neovascular AMD has changed markedly over the past
decade because anti-vascular endothelial growth factor
(VEGF) drugs can slow progression of this form of the* Correspondence: rosa@ioba.med.uva.es
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unless otherwise stated.disease [2]. In pivotal clinical trials, ranibizumab was
administered every month for 2 years and good functional
results were obtained. However, subsequent studies
theorized that a judiciously administered course of
variable-frequency pro re nata intravitreal ranibizumab
treatment preserves vision in three quarters of patients
and improves vision in one third becoming the accepted
protocol [3,4]. Several authors have reported clinical
practice outcomes and adherence to this treatment
regime in different European countries [5-7], but only one
study presented results beyond 1 year of follow-up [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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early age-related maculopathy (ARM) to late ARM defined
as the occurrence of geographic atrophy (GA) or neovas-
cularization [9]. In contrast, little has been reported about
evolution of this condition once the neovascular form of
the disease is established, appart from the Comparison
of Age-Related Macular Degeneration Treatment Trial
(CATT) that found that about half of eyes developed a
fibrotic scar by 2 years [10]. We also need to know more
about how anti-VEGF drugs modify those processes,
mainly in long follow-up treatments [8,11,12].
The aims of the current study were to survey the ana-
tomic and functional outcomes after longstanding treat-
ment of AMD with ranibizumab (Lucentis, Genentech,
Inc., South San Francisco, CA) in the Castilla y Leon region
of Spain, and verify the performance of a new formula that
allows comparing retinal thickness measured with different
optical coherence tomography (OCT) tools.
Methods
We performed a retrospective, observational case series
study in seven centers in the Castilla y Leon region of
Spain. We searched our databases for patients treated
with ranibizumab. We also identified all patients with
AMD and reviewed their medical charts systematically.
This research followed the tenets of the Declaration of
Helsinki. The Institute of Applied Ophthalmo-Biology
(IOBA) requested the approval of the study protocol to
the Clinical Research Ethics Committee -Health Area
East- of Valladolid (CEIC-VA-EAST-HCUV) with the ref-
erence number EPA-12-100; and thereafter the Research
Commission of the Complejo Asistencial de Palencia, of
the Hospital Universitario de Valladolid, of the Complejo
Asistencial Universitario de Leon, of the Complejo
Hospitalario de Segovia, of the Hospital Universitario
de Salamanca, and of the Complejo Asistencial de Avila
adhered to this approval. This research followed the
tenets of the Declaration of Helsinki.
Patients included had treatment-naive exudative AMD
and started treatment between January 1, 2008, and
December 31, 2010, with intravitreal ranibizumab fol-
lowing the Spanish Society of Retina and Vitreous protocolTable 1 Data on participant centers
Hospital Number of eyes included Retino
IOBA (University of Valladolid) 31 TCR50
Care complex of Palencia 56 FF450
University hospital of Valladolid 67 TCR50
Care complex of Avila 19 TCR50
Care complex Salamanca 32 TCR50
Care University complex of Leon 66 FF450
Care complex of Segovia 43 TCR50treatment [4]. Spanish and European guidelines recom-
mended at that time a loading dose consisting of three
initial consecutive monthly injections and thereafter an
as needed treatment, also known as pro re nata (PRN),
where injections are administered when visual acuity
loss and signs of lesion activity occur [13,14]. Patients
were excluded with other associated pathologies that
might cause visual loss, late baseline AMD, and patients
who did not complete at least 24 months of follow-up.
We recorded age, sex, affected eye, date of diagnosis,
age, angiographic lesion type, associated fundus lesions
and lens status, and the macular status of the contralateral
eye at baseline. The Snellen distance best-corrected visual
acuity (VA), OCT assessment, and the number of visits
and injections were harvested at baseline, 3 months, and
at 1, 2, 3, and 4 years of follow-up. Snellen readings were
converted into the logarithm of the minimum angle of
resolution [logMAR] value equivalent using a validated
procedure.
OCT was performed in each patient at each visit. The
central macular thickness was measured in microns by
OCT (Table 1); we also gathered data on OCT morph-
ology (presence or absence of subretinal fluid and/or
thickening >100 microns compared to the previous visit).
To avoid the effect of using different instruments and to
analyze the OCT thickness, we calculated the percentage
change in the retinal thickness of each patient, thus com-
paring each patient with themselves and their own tool.





if thicknessm > thicknessi
0 if thicknessm ¼ thicknessi
thicknessm−thicknessi
thicknessi−thicknessmin
if thicknessm < thicknessi
8>><
>>:
where thicknessm is the foveal thickness at time m,
thicknessi is the foveal thickness at baseline, thicknessmax
and thicknessmin are, respectively, the minimum and
maximum values of foveal thickness from each corre-
sponding OCT tool. Δthickness*100 can be interpreted
as the percentage change compared to the initial foveal
thickness; if positive it indicated a thickening retina andgraphy-angiography tool OCT tool
IX (Topcon) 3D OCT-2000 (Topcon)
plus IR (Carl Zeiss Meditec©) OCT 4.0.7 (Carl Zeiss Meditec©)
DX (Topcon) 3D OCT-1000 (Topcon)
DX (Topcon) 3D OCT-1000 (Topcon)
DX (Topcon) Cirrus HD-OCT 4000 (Carl Zeiss Meditec©)
plus IR (Carl Zeiss Meditec©) Cirrus HD-OCT 4000 (Carl Zeiss Meditec©)
X (Topcon) Stratus 6.0.2 (Carl Zeiss Meditec©)
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means 35% decrease in thickness of the initial value).
Initial fluorescein angiography (FA) was performed
before treatment in most eyes; indocianine green angi-
ography was also performed on suspicious cases of
polypoidal choroidal vasculopathy (PCV) and in patients
with initial poor response to treatment. The initial angio-
graphic characteristics of the lesions were grouped as
classic-predominantly classic, occult-minimally classic,
PCV, and others. The presence of basic macular-associated
lesions was recorded at baseline, 3 months, and 1, 2, 3, and
4 years after treatment, including major bleeding 50%,
retinal pigment epithelial (RPE) detachment, RPE tear,
atrophy, retinal angiomatous proliferation, and others.
To classify the funduscopy results (viewed on FA or
OCT photographs) from the contralateral eye, we used
the International ARM classification [15]. The final fundu-
scopic status (viewed on FA or OCT photographs) of the
studied eye was classified as an inactive predominantly
fibrotic disciform scar, inactive predominantly atrophic
scar; inactive well-preserved macular retina, active lesions
on OCT (thickening of retina >100 microns or subretinal
fluid, with/without blood and/or lipid exudates), and
unclassifiable (Figures 1, 2, 3 and 4).
If the patient discontinued treatment after the second
year, we recorded the cause as patient decision, medical
decision due to secondary effects, medical decision due
to lack of efficacy and deceased.
Statistical analysis
The distributions of quantitative variables are expressed
as the mean, standard deviation (SD), median, minimum,
and maximum. Normally assumption was checked using
the Lilliefors correction Kolmogorov-Smirnov test or
Shapiro-Wilks test for small sample sizes (<50 individ-
uals). Qualitative variables were expressed as percentages
with 95% confidence intervals (CIs).
The Pearson chi-square test was used to evaluate the
relationship between two qualitative variables. WhenFigure 1 Disciform fibrotic scar final outcome. This patient, followed fo
Initial logMAR VA was 0,8(20/125) and final logMAR VA 0,5 (20/63); a) initiaexpected frequencies were small, the Fisher’s exact test
was used. Spearman’s rank correlation coefficient was
calculated to identify and test the strength of the rela-
tionship between two qualitative variables. A bootstrap
percentile CI for this coefficient, at a 95% level of confi-
dence, was constructed based on 5,000 replications. The
Student’s t-test or its non-parametric alternative, the
Mann–Whitney U, was used to test differences between
the means of two independent groups if the normality
assumption was not valid. With more than two groups,
analysis of variance (ANOVA) or non-parametric Kruskal-
Wallis ANOVA was performed to test the global hypothesis
of equal means followed by a post-hoc analysis with the
Bonferroni correction. All these tests assume the variances
of the groups are equal, the homogeneity of variance as-
sumption. Levene’s test was used to test this hypothesis. If
Levene’s test indicated unequal variances, Welch’s test was
used in parametric cases. The two-sample Kolmogorov-
Smirnov test and a transformation of the data were used as
alternatives to the Mann–Whitney U test and Kruskal-
Wallis ANOVA test, respectively.
To analyze the evolution of VA and account for re-
peated measurements over time for each subject, linear
mixed-effects models with random intercepts and random
slopes were estimated. Time was modelled as a categorical
variable instead of a continuous variable, without assum-
ing a specific shape of its relationship to VA.
Statistical analysis was performed using R Statistical
Software (R Core Team; Viena, Austria) [16]. The lme4
package (Douglas Bates, Martin Maechler, Ben Bolker
and Steven Walker; R package version 1.1-6) was used
to fit linear mixed-effects [17].
Results
We evaluated 1,236 eyes treated with anti-VEGF drugs at
seven hospitals, of which 314 eyes of 299 patients (177
women, 122 men); mean age, 78.3 years (range, 55–94;
SD, 7.4) were included in the current study. Patients were
withdrawn because they did not have AMD, had not beenr 2 years, needed 6 injections along the 1st year and 2 the 2nd year.
l fundus photograph; b) final fundus photograph.
Figure 2 Evolution to atrophy. This patient followed for 3 years and 7 months needed only the 3 first injections of the loading phase and none
thereafter; a) initial fundus picture showed lipidic exudates at the superior border of the lesion; c) initial OCT showed intraretinal and subretinal fluid
and logMAR VA was 0.8 (20/125). A year later she a year later she began developing atrophy which increased over the years; b) fundus final picture;
d) final OCT status; e) final autofluorescence with atrophy not affecting the fovea which explains a final logMAR VA 0,2 (20/32).
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completed the loading dose or the minimum required
follow-up, or the clinical charts were incomplete.
The mean follow-up was 1,155.4 ± 349.1 days (range,
722–1,970). The final VA was significantly (P = 0.02) bet-
ter (lower logMAR value) beyond the third year in eyes
for which treatment started in 2010. The mean time to
treatment was 17.3 days (range, 0–60; SD, 14.6; median,
12). Eyes treated before 21 days had a greater improve-
ment in VA (lower logMAR value) that only reached
significance (P = 0.02) at 3 months. Results according to
the initial VA are presented in Table 2.
Regarding 55 eyes for which treatment was discontin-
ued, 12 patients stopped treatment and 12 died, physicians
stopped treatment because of secondary effects (2 eyes) or
lack of efficacy (25 eyes), and 4 eyes stopped for other
reasons. An increase in the logMAR VA (vision worsen-
ing), percentage of patients with subretinal fluid or retinal
thickening over 100 microns, and number of injections
were significantly (P < 0.0001) higher after the second year
in this patient subgroup.
Nine eyes needed a treatment change along follow-up
because of no response or a partial response (19 eyes), 5
eyes due to secondary effects and 5 for other reasons.
We observed ocular or systemic complications in fourpatients (two eyes had a RPE tears; two had a stroke,
and one had thrombosis) throughout the study period.
Ninety-two eyes were pseudophakic at baseline. This
subgroup of eyes did not need more injections at any time
point, and compared to phakic eyes, they needed signifi-
cantly (P = 0.04) fewer injections during the second year.
The VA results are shown in Table 3 and Figure 5. The
eyes with final VA > 20/50 Snellen acuity needed signifi-
cantly (P = 0.02) fewer injections and visits but only
during the fourth year compared to the rest of the eyes.
The patient age was significantly (P = 0.0003) younger in
this subgroup of patients. In eyes with final VA < 20/200
Snellen acuity, the decrease in the retinal thickness was
significantly (P = 0.02) lower during the third month
than in the rest of the eyes; significantly (P = 0.003) more
injections were administered during years 1 and 2 in
eyes that lost more than two lines of VA compared to
the rest. The patient age was significantly (P = 0.0002)
older in this subgroup. Thus, patients under 75 had
significantly (P < 0.03) better visual outcomes at all time
points.
The retinal thickness decreased by 30% to 35% of the
baseline value at all time points; the decrease in thickness
was significant (P < 0.0001) at 3 months and remained
stable throughout the follow-up period (Table 3). Patients
Figure 3 Active lesion at the final visit. Initial fundus (a) of a patient followed for 4 years showed neither blood nor lipidic exudates and
logMAR VA was 0.7(20/100); b) fluorescein angiography displayed an occult CNV. The patient needed 4 injections de 1st year, 2 along the 2nd
year, 1 during the 3rd year, and none during the 4th year until the last visit in which a reactivation was observed with blood in fundus picture
(c) and subretinal fluid in OCT (d). Final VA was 0.4 logMAR (20/50).
Figure 4 Well preserved retina at final visit. This patient needed 10 injections all along the 4 years of follow-up. Initial logMAR VA was 0.5(20/63); a)
initial fundus picture; b) fluorescein angiography showed a predominantly classic choroidal neovascularization. Final picture (c) shows a well-preserved
retina, neither with evident fibrosis, nor with atrophy on autofluorescence (d); final VA was 0.3 (20/40).
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G1 vs G2 G1 vs G3 G2 vs G3
VA 3 months 0.25 ± 0.31 0.62 ± 0.37 1.23 ± 0.5 <0.0001 <0.0001 <0.0001 <0.0001
VA 1 year 0.26 ± 0.31 0.75 ± 0.45 1.28 ± 0.57 <0.0001 <0.0001 <0.0001 <0.0001
VA 2 year 0.44 ± 0.45 0.98 ± 0.6 1.36 ± 0.57 <0.0001 <0.0001 <0.0001 <0.0001
VA 3 year 0.59 ± 0.52 1.02 ± 0.61 1.38 ± 0.69 <0.0001 0.0009 <0.0001 0.0093
VA 4 year 0.58 ± 0.46 1.08 ± 0.59 1.53 ± 0.48 <0.0001 0.0054 0.0001 0.0036
N Injections 3 months 2.64 ± 0.49 2.65 ± 0.49 2.58 ± 0.5 0.604 1 1 0.9569
N Injections 1 year 4.31 ± 1.95 4.09 ± 1.46 3.39 ± 1.18 0.0006 1 0.0356 0.0004
N Injections 2 year 1.41 ± 1.67 1.23 ± 1.61 0.61 ± 1.16 0.0025 1 0.0352 0.0023
N Injections 3 year 2.22 ± 2.58 1.48 ± 2.45 1.38 ± 2.05 0.1571 0.194 0.2912 1
N Injections 4 year 2.67 ± 3.5 1.8 ± 3.26 1.65 ± 2.18 0.4688 0.7252 1 1
N Visits 3 months 3 ± 0.69 2.71 ± 0.77 2.54 ± 0.75 0.0325 0.1425 0.0237 0.5999
N Visits 1 year 7.64 ± 2.19 7.41 ± 2.09 6.94 ± 2.36 0.3902 1 0.7785 0.66
N Visits 2 year 4.91 ± 2.85 5.36 ± 2.55 5.22 ± 2.93 0.4769 0.7832 1 1
N Visits 3 year 4 ± 2.6 4.13 ± 2.35 3.41 ± 2.34 0.1449 1 1 0.1457
N Visits 4 year 3.77 ± 2.77 3.81 ± 2.16 3 ± 2.25 0.2883 1 1 0.3264
Age (years) 75.28 ± 8 78.31 ± 7.36 80.1 ± 7.21 0.0092 0.0939 0.0109 0.2121
VA Visual Acuity, N number, G1 group 1, G2 group 2, G3 group 3, vs versus.
Statistical significant p values are in bold.
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in retinal thickness at 3 months and 2 and 4 years. There
was a significant (P = 0.04) negative correlation between
the change in retinal thickness and VA at the third month.
The changes in OCT morphology are shown in Figure 6.
We had FA images for only 206 eyes. Of them, 125
(60.7%) eyes had classic or predominantly classic CNV;
75 (36.4%) eyes had occult or minimally classic CNV;
and six (2.9%) eyes had other FA patterns at baseline; 14
eyes showed PCV throughout the study. Classic CNV
showed more signs of activity on OCT images than occult
membranes at 4 years (Figure 7). The VA was significantly
(P = 0.01) lower during the fourth year in eyes with PCV,
and this subtype of AMD needed significantly (P = 0.03)





Initial 314 O.8 (20/125) ± 0.5/0.7
3 months 314 0.7(20/100) ± 0.5/0.6 −0.35 ± 0.
1st year 314 0.8(20/125) ± 0.5/0.7 −0.32 ± 0.
2nd year 314 1(20/200) ± 0.6/0.8 −0.3 ± 0.4
3rd year 229 1(20/200) ± 0.6/1 −0.3 ± 0.4
4th year 109 1.1(20/250) ± 0.6/1 −0.31 ± 0.
Final/total 314 1.1(20/250) ± 0.6/1 −0.33 ± 0.
N number, SD Standard Deviation.Regarding associated lesions at baseline, 100 (31.8%)
eyes had bleeding of more than 50% of the lesions, 59
(27.6%) eyes had a RPE detachment, two (0,6%) eyes had a
small RPE tear, nine (4.2%) eyes had GA at the macular
area, seven (3.3 eyes had angiomatous retinal proliferation,
and four (1.9 %) eyes had PCV diagnosed at the study on-
set (the rest of the PCV were diagnosed along the study).
The numbers of visits and injections are shown in
Table 3. All eyes received injections during the first year,
but 150 eyes did not need any injections during the
second year, 122 of 229 eyes did not receive injections
during the third year, and 57 of 109 eyes did not receive
injections during the fourth year. There was a significant
(P < 0.001) positive correlation between the number of






35 2.7 ± 0.8 2.6 ± 0.5
4 7.3 ± 2.1 3.9 ± 1.5
5.2 ± 2.7 1.1 ± 1.5
3.9 ± 2.3 1.5 ± 2.4
4 3.6 ± 2.2 1.8 ± 3.1
4 17.7 ± 7.6 6.8 ± 5,1
Figure 5 Box plot showing the evolution of VA along the study. Mean VA is presented in dashed line and median in solid line.
Coco et al. BMC Ophthalmology 2014, 14:138 Page 7 of 12
http://www.biomedcentral.com/1471-2415/14/1383 months. Patients receiving more than 5 injections a
year had a lower logMAR VA at 3 month than patients
receiving less intensive treatment (p = 0,0121), differ-
ences were also near the significance at the initial visit
(p = 0,0579). Moreover, change in VA was 15-20% in
patients receiving >5 injections compared to the patients
receiving less intensive treatment, being the differences
statistically significant at year 4th (p = 0,0471) and at the
final visit (p = 0,0188). Finally, the percentage of active
lesions at final visit was higher in patients receiving
more intensive treatment (p = 0,0378).Figure 6 Data on OCT morphology along the study.Concerning the baseline status of the fellow eyes, 114
(39.1%) eyes had early ARM; 29 (9.8%) eyes had wet
AMD; 59 (20%) eyes already had a fibrotic disciform scar
due to wet AMD; and 54 (18.3%) eyes had GA. Seventy-
six (66%) of 114 eyes with baseline early ARM were
stable at the end of the study, 28 (24.3%) eyes progressed
to CNV (three developed a disciform fibrotic scar), and
10 developed GA.
Regarding the final macular anatomy, we had data on
fundus photographs of 287 eyes. One hundred and seven
(37.2%) eyes had a fibrotic disciform scar, 89 (31.0%)
Figure 7 Baseline CNV patterns at FAG versus signs meaning
activity at OCT.
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still had active lesions, 49 (17.1%) eyes had a relatively
well-preserved macular appearance; and five eyes (1.7%)
were unclassifiable.
According to final anatomy compared to initial VA, we
found that patients with initial VA <0,3 had lower percent-
age of disciforms scar and higher preserved macula at final
visit than patients with initial VA >0,1 (p = 0,0005).
The eyes with a final logMAR VA below 0.4 (>20/50
Snellen acuity) had fewer disciform scars and more
preserved maculas (P < 0.0001) than eyes with a worse
visual outcome. Disciform maculas had a higher final
logMAR VA (lower Snellen fraction value) than maculas
with active lesions (P = 0.003) or preserved (P = 0.0001)
maculas. These lesions needed fewer injections (P = 0.0004)
than the rest. The decrease in thickness was greater than in
eyes with active lesions and atrophic eyes (P = 0.004) during
the third month; that decrease persisted and significantly
(P = 0.01) surpassed the rest at the final visit. We did not
find a specific association with the presence of more than
50% bleeding at baseline or retinal thickness.
Preserved maculas had a significantly (P = 0.002) lower
final logMAR VA (better Snellen fraction) than atrophic
maculas. The preserved maculas had no RPE tears or
PCV lesions (P = 0.01). The percentage of well-preserved
retinas was higher in patients who started treatment
in 2010.
The percentage of active lesions was significantly
(P = 0.03) higher in the subgroup that needed more
than five injections during the first year, in addition,
VA improvement (P = 0.006) and decreased thickness
(P = 0.04) during the third month were lower compared to
the eyes with other macular status. The decrease in retinal
thickness was less in maculas with active disease than ineyes with preserved maculas at 1 year (P = 0.01) and the
final visit (P = 0.002). This active subgroup also needed a
treatment change more frequently, and this difference
trended toward significance (P = 0.056); these eyes also re-
ceived significantly (P < 0.0001) more injections compared
to the rest.
Atrophic maculas had a significantly (P = 0.005) worse
initial VA before Bonferroni correction and this remained
at borderline significance (P = 0.05). This type of final out-
come was significantly (P = 0.02) lower in patients treated
after 2010, who also showed a greater decrease in thick-
ness during the third month compared with those with
active disease and lower than in those with disciform scars
(P = 0.003).
Discussion
The current study is one of the largest published cohort
studies in Europe [5-7], and also has on of the longest
follow-up to date (mean, up to 3 years) [8].
We found the best visual and OCT results in patients
younger than 75 years, and the mean age of our popula-
tion exceeded that value. We think that the advanced
age in the current series may explain partly the poor
final visual outcomes.
The average initial VA (0.8 logMAR, 20/125 Snellen
acuity) of our eyes was similar to the mean initial VA in
the ANCHOR (47 letters = 20/250) [18], MARINA (53.4
letters = 20/160) [19], or PrONTO (56.2 letters = 20/160)
studies [20], and similar to the results found in other
clinical practice studies (Table 4). Nevertheless, the ini-
tial VA was much worse than in the study of Rasmunsen
et al. [8] (Table 4), which may be associated with later
disease diagnosis in our region and to higher chronicity
and larger lesions in these eyes at the beginning of the
study. This difference also may explain the better final
VA reported by Rasmunsen et al.; in that study the
vision was maintained, but not when the baseline level
was better [8].
We observed an improvement in VA at the 3-month
visit that remained stable thereafter until the first year,
but afterwards it started to decrease, as in other studies
[8,11,12], confirming that the visual improvement was
not maintained over the long-term despite treatment
[21]. This may have several explanations. First, the
current study was longer than any other, except for the
HORIZON [11], SEVEN-UP [12], and Rasmunsen et al.
[8], studies. The SEVEN-UP study concluded with a loss of
vision after 7 years of follow-up and visual loss started after
the second year of treatment. Furthermore, Rasmunsen,
with a similar follow-up to our report, reported stable VA
during the study but when the subgroups were evaluated,
the patients with better initial VA clearly lost sight after
4 years of treatment [8]. Finally, no significant VA changes
occurred in eyes with the poorest initial VA, indicating that




















1.8 ± 3.1 6.4
Initial
logMAR VA
O.8 0.86 (53.2 letters) 0.98 (48.8 letters) 1 (45.1 letters) 0.92 (56.3 letters) 0.76 (58.3 letters) 0.6 (0.24 Snellen)
1st year
logMAR VA
0.8 0.92 (gain 3.2 = 56.4 letters) 0.96 (48.0 letters) 1.02 (50.7 letters) 0.78 (58.8 letters) 0.78 (59.3 letters) 0.5 (0.35 Snellen)
Final logMAR
VA (4th y)
1 0.8 (0.18 Snellen)
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ment [12], and the patients in the current series did not
have a good mean initial VA.
Moreover, we obtained the best VA results if the first in-
jection was administered before 21 days, but this effect was
seen only during the first 3 months. This is important be-
cause the findings indicated that the interval between diag-
nosis and the first injection is key to the prognosis [6,22].
After the third month, we found no differences in eyes
treated before 3 weeks, which may have been because of
the fewer injections compared with other studies (Table 4).
We observed a better outcome (higher number of well-
preserved maculas and fewer atrophic eyes) in eyes that
started treatment after 2010, but the number of eyes in
this group was low and the shorter follow-up period may
explain this result, as patients are less evolved. They also
may have had better compliance with protocols, as the
LUMIERE study found [6].
The regimen used in the current study, i.e., “wait and ex-
tend”, was similar to that reported by Arias et al. [14], but
it may well be that more proactive treatments led to better
visual results [23,24]. Further, fewer injections were admin-
istered during the first year compared with the SUSTAIN
[25], LUMIERE [6], and PrONTO [20], studies (Table 4).
However, we must consider that the number of visits was
greater than the injections administered each year in the
current study, so the doctors decided not to treat, and the
data on the activity seen in the OCT images are consistent
with that decision. Finally, the number of annual injections
decreased over time in the current study, which differed
from the results of Rasmunsen et al. (Table 4) [8]. However,
treatment did not stop completely and we found a substan-
tial percentage of patients with active lesions at the last
visit, indicating that AMD is a chronic disease and patients
should not be discharged, although a well-trained general
ophthalmologist can help in that follow-up.
In addition, there was poor compliance with recom-
mendations regarding the loading phase, as this was afrequent cause to withdraw patients, although those
patients were not included in the current study. Moni-
toring also was not as rigorous as recommended (Table 4),
although it was similar to but worse than other clinical
practice studies [5,6], partly perhaps because of the ad-
vanced age of our population.
Moreover, the fact that we found better VA and OCT
outcomes in eyes treated with more injections confirms
that the more proactive the treatment, the better the re-
sults. Nevertheless, first those with no signs of activity in
the variable OCT morphology are those who received
fewer injections, and second those with classic CNV re-
ceived more injections, which was reported previously
[26]. Therefore, it is also possible that the fewer injec-
tions administered in the current study compared with
other studies [6,14,27,28] might have been due to the
special characteristics of our population, i.e., two thirds
of patients had poor initial VA, older age, and rapid de-
velopment of disciform or atrophic scars. We also be-
lieve that fewer injections and visits, compared with
previous studies [6,14,27,28], could have resulted from
saturation of healthcare institutions, and treatment and
follow-up burden on patients and physicians.
PCV showed more signs of activity on OCT, worse
VA, and need for more injections. Poor outcomes after
treatment with ranibizumab have already been reported
with this AMD subtype [29].
In the current study 60% of patients had classic CNV,
which differed from other studies in which occult CNV
developed more frequently [30]. Patients with classic
CNV had more signs of activity on OCT images as pre-
viously reported [31], and this also may have affected
our results. The fact that eyes with a worse final VA had
less decrease in macular thickness indicated poorer
treatment response, which may be related to more cases
of classic CNV compared to other studies [32]. Patients
with worse visual results received more injections during
the first 2 years, which may have been related to the
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found worse results in more active lesions.
Main reasons for treatment changes or discontinuation
were no response or a partial response, which occurs in
an important percentage of patients. In addition, patients
who dropped out had poorer visual results and thicker
retinas, but interestingly they also received more injections
so that the latter may be excluded as a possible explan-
ation. We also had few complications and at the expected
rate (<1%) [5,33]. Thus, ranibizumab had a favorable safety
profile for treating wet AMD over a 4-year period in real-
world clinical practices.
Theoretically, postoperative anatomic and physiologic
changes can affect the pharmacokinetics of intravitreal
injected drugs [34]. Nevertheless, pseudophakic eyes did
not need more injections, which confirmed the findings
of another study [35].
The formula for the changes in retinal thickness
worked well and may be one of the most important
contributions of this paper, as can be applied in other
studies comparing data obtained with different OCT
tools. The decreased thickness evident at month 3 that
remained stable throughout the study correlated with
SRF disappearance and the absence of macular thickening
seen on OCT morphology data. The good correlation
between retinal thickness changes measured that way and
morphology on OCT shows that it works well. This good
anatomic outcome also may explain the lower number of
injections.
Regarding fellow eyes, 28 of the 114 eyes with early
ARM at baseline developed CNV, and 10 developed at-
rophy during the study period. This was not comparable
to other published results, because other authors study-
ing the progression of early ARM had longer follow-up
periods [9].
Fibrosis was observed in one third of eyes during the
final funduscopic evaluation in the studied eye, another
third had atrophy, and about 13% had signs of activity.
This also explains the poor final VA results, with more
than two thirds of patients having a macular status that
can not end with good VA.
Logically, the VA was worse in eyes with disciform scars
and better in eyes with preserved retinas. Interestingly, the
disciform lesions needed fewer injections than the rest
and we found no relationship with more than 50% of
bleeding lesions at baseline as the CATT found [10]. We
also found more preserved retinas in patients treated after
2010 possibly due to a shorter time of evolution or better
treatment compliance as the LUMIERE study reported [6].
Active lesions at the final visit required more than five
injections the first year, but VA improvement and the
decreases in retinal thickness throughout the study were
lower. We also found greater changes in treatment and
increased numbers of injections in this subgroup. Thesedata were expected, but they indicate that these eyes did
not receive less treatment, but they received more injec-
tions, and there was poorer response, which is why they
needed more frequent change in treatment.
Maculas that were atrophic at the final visit had a
worse initial VA and the decrease in thickness at month
3 was greater. Those were the only baseline risk factors
identified for the final atrophic outcome.
The current study had limitations. The first was its
retrospective nature, as the information in medical
records is not intended for research and does not always
contain all the information that should be collected
[36,37]. An important limitation was the high number of
initial dropouts, although the final number of eyes ana-
lysed treated homogeneously counteracted this effect. Also
patients not responding to treatment may be more likely
to drop out than patients responding well which could
have improve final outcomes. Nevertheless we have to
remind that we had data on 55 patients discontinuing
treatment and we know from them that only half (n = 25)
stopped treatment because of lack of efficacy and this
group also showed some other factors of worse prognosis
such as worsening of vision, more presence of subretinal
fluid, higher retinal thickening and higher number of
injections. Finally, the VA estimates were recorded as
Snellen acuity and converted to the logMAR equivalent,
which is not perfect but generally accepted as robust [38].
Conclusions
In summary, younger patients had better final outcomes.
The initial VA in the current study was poor. Fewer
injections were administered than in other studies but
several reasons explains that, and also the number of visits
was higher than the number of injections. Our formula
for comparing retinal thickness using different OCT tools
worked well. The final visual outcome with a long follow-
up showed poor VA results, which was correlated with the
macular status that does not allow obtaining better results.
Eyes with disciform scars needed fewer injections; long-
term activity was correlated with lesions that had a worst
treatment response; and atrophy was seen more frequently
at the final visit in patients with less decrease in retinal
thickness at month 3 and a worse initial VA. Finally, mac-
ulas had a greater chance of remaining well preserved at
the final visit if treatment started after 2010 and if there
was no PCV or RPE tears.
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